Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
3 reports, 3 independent
Updated Jul 30
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Agios Pharmaceuticals
a public American pharmaceutical company
Nothing else this week.
- FDA
Related events
- Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- Inventiva seeks FDA approval for lanifibranor in the U.S. market.